The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding $853,000 to researchers at UNSW Sydney and Donum Therapeutics to advance a new class of antibiotics designed to kill multidrug-resistant bacteria that cause serious infections. Antimicrobial resistance is a fast-growing global public health challenge that is far outpacing the development of new antibiotics. The researchers are working to re-engineer a naturally occurring peptide antibiotic, darobactin, discovered in 2019 to make it more suitable for use as a treatment. Darobactin works by targeting a novel target in the outer walls of bacterial cells, which no antibiotics currently on the market target, making it well-suited to address multidrug-resistant strains of bacteria.
A new study published in JAMA Network Open found that a recently approved mRNA vaccine for respiratory syncytial virus (RSV) infection provided strong protection against serious cases in older adults. The large study, assessing veterans 50 years and older in the United States, found that the vaccine worked across ages, was especially effective against RSV-associated hospitalizations, and demonstrated similarly efficacy to other non-mRNA RSV vaccines, although it demonstrated decreasing efficacy with increasing age. The vaccine was approved by the US Food and Drug Administration in 2024 for adults 60 and older; the approval was later expanded to include younger adults at increased risk of lower respiratory tract disease caused by RSV.
Last week, the Pan American Health Organization (PAHO) announced that it has negotiated a landmark regional agreement to improve access to more affordable, high-quality human papillomavirus (HPV) testing in the Latin America and the Caribbean region. HPV infection causes nearly all cases of cervical cancer, which is highly preventable through vaccination, screening, and timely treatment. However, countries across the region have faced some of the highest HPV test prices in the world, limiting uptake, alongside other technical and programmatic barriers. Through the agreement, countries in the region will be able to access high-quality molecular HPV tests through preferential pricing and a comprehensive support package, with cost savings ranging from 30 to 70 percent. The agreement also includes support for implementation, equipment, and training.